drugset / Trial / NCT03760809

Dexmedetomidine Combined With Hydromorphone in Tonsillectomy and Adenoidectomy

NCT03760809

Phase 4 Completed 130 enrolled Eye & ENT Hospital of Fudan University
RandomizedParallel-groupTriple-blindSupportive care

Summary

Tonsillectomy and adenoidectomy is one of the most common pediatric surgeries, and agitation and severe postoperative pain have been considered a very common complications. Dexmedetomidine mainly inhibits the release of norepinephrine by acting on the α-adrenergic receptor of the brainstem nucleus, which can produce good sedative effects. Hydromorphone has a longer duration of action than fentanyl, and it also has a certain sedative effect. The combination of the two is more conducive to the management of postanesthetic agitation and pain. This study was to compare the effect of different doses of dexmedetomidine combined with hydromorphone in the sedation and analgesia after pediatric tonsillectomy and adenoidectomy.

Timeline

Start
2019-01-04
Primary completion
2019-02-10
Completion
2019-04-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg
Subject Dexmedetomidine Other / unclassified 1 ug/kg
Background Hydromorphone Other / unclassified 0.03 mg/kg

Indications